Coronary diagnostics company AngelMed recently marked its first commercial implantation of its cardiac detection monitor in the U.S.
The FDA-approved Guardian system is a patient warning system used for acute coronary syndrome events, including silent heart attacks, according to a July 27 press release.
The device was implanted during an outpatient procedure performed by Andrew Kaplan, MD, at Cardiovascular Associates of Mesa in Arizona. Dr. Kaplan was a clinical trial investigator for the system and serves on the company's medical advisory board.